Generic Name:
indacaterol glycopyrronium mometasone furoate
Project Status:
Complete
Therapeutic Area:
Asthma maintenance, adults
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Enerzair Breezhaler
Project Line:
Reimbursement Review
Project Number:
SR0645-000
Call for patient/clinician input closed:
Details
Manufacturer Requested Reimbursement Criteria1:
Indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.